PMC:7212965 / 79682-80149 JSONTXT

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T187","span":{"begin":248,"end":253},"obj":"Body_part"}],"attributes":[{"id":"A187","pred":"fma_id","subj":"T187","obj":"http://purl.org/sig/ont/fma/fma7197"}],"text":" Fu, 202066Third People’s Hospital of Kunming (Kunming)YunnanDates: 1/26/2020-2/15/2020Last follow-up: NR n = 36Survival: 17% discharged, 6% ICU, 78% still hospitalized.Inclusion: Inpatients with COVID-19 based RT-PCR.Age: 45 ySex: 55.6% femalesGI/liver comorbidities: NRDisease severity: mild 11% (4), common 83% (30), severe, critical 6% (2) Diarrhea: % (3)Present on admissionVomiting, nausea, and abdominal pain: NR AST 11.1% (4)ALT 11.1% (4)Bilirubin 30.56% (11)"}

{"project":"LitCovid-PD-UBERON","denotations":[{"id":"T152","span":{"begin":248,"end":253},"obj":"Body_part"}],"attributes":[{"id":"A152","pred":"uberon_id","subj":"T152","obj":"http://purl.obolibrary.org/obo/UBERON_0002107"}],"text":" Fu, 202066Third People’s Hospital of Kunming (Kunming)YunnanDates: 1/26/2020-2/15/2020Last follow-up: NR n = 36Survival: 17% discharged, 6% ICU, 78% still hospitalized.Inclusion: Inpatients with COVID-19 based RT-PCR.Age: 45 ySex: 55.6% femalesGI/liver comorbidities: NRDisease severity: mild 11% (4), common 83% (30), severe, critical 6% (2) Diarrhea: % (3)Present on admissionVomiting, nausea, and abdominal pain: NR AST 11.1% (4)ALT 11.1% (4)Bilirubin 30.56% (11)"}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T378","span":{"begin":196,"end":204},"obj":"Disease"},{"id":"T379","span":{"begin":344,"end":352},"obj":"Disease"}],"attributes":[{"id":"A378","pred":"mondo_id","subj":"T378","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A379","pred":"mondo_id","subj":"T379","obj":"http://purl.obolibrary.org/obo/MONDO_0001673"}],"text":" Fu, 202066Third People’s Hospital of Kunming (Kunming)YunnanDates: 1/26/2020-2/15/2020Last follow-up: NR n = 36Survival: 17% discharged, 6% ICU, 78% still hospitalized.Inclusion: Inpatients with COVID-19 based RT-PCR.Age: 45 ySex: 55.6% femalesGI/liver comorbidities: NRDisease severity: mild 11% (4), common 83% (30), severe, critical 6% (2) Diarrhea: % (3)Present on admissionVomiting, nausea, and abdominal pain: NR AST 11.1% (4)ALT 11.1% (4)Bilirubin 30.56% (11)"}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T606","span":{"begin":223,"end":225},"obj":"http://purl.obolibrary.org/obo/CLO_0053799"},{"id":"T607","span":{"begin":248,"end":253},"obj":"http://purl.obolibrary.org/obo/UBERON_0002107"},{"id":"T608","span":{"begin":248,"end":253},"obj":"http://www.ebi.ac.uk/efo/EFO_0000887"},{"id":"T609","span":{"begin":294,"end":301},"obj":"http://purl.obolibrary.org/obo/CLO_0053001"},{"id":"T610","span":{"begin":464,"end":466},"obj":"http://purl.obolibrary.org/obo/CLO_0053733"}],"text":" Fu, 202066Third People’s Hospital of Kunming (Kunming)YunnanDates: 1/26/2020-2/15/2020Last follow-up: NR n = 36Survival: 17% discharged, 6% ICU, 78% still hospitalized.Inclusion: Inpatients with COVID-19 based RT-PCR.Age: 45 ySex: 55.6% femalesGI/liver comorbidities: NRDisease severity: mild 11% (4), common 83% (30), severe, critical 6% (2) Diarrhea: % (3)Present on admissionVomiting, nausea, and abdominal pain: NR AST 11.1% (4)ALT 11.1% (4)Bilirubin 30.56% (11)"}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T155","span":{"begin":103,"end":105},"obj":"Chemical"},{"id":"T156","span":{"begin":417,"end":419},"obj":"Chemical"},{"id":"T157","span":{"begin":420,"end":423},"obj":"Chemical"},{"id":"T158","span":{"begin":446,"end":455},"obj":"Chemical"}],"attributes":[{"id":"A155","pred":"chebi_id","subj":"T155","obj":"http://purl.obolibrary.org/obo/CHEBI_145751"},{"id":"A156","pred":"chebi_id","subj":"T156","obj":"http://purl.obolibrary.org/obo/CHEBI_145751"},{"id":"A157","pred":"chebi_id","subj":"T157","obj":"http://purl.obolibrary.org/obo/CHEBI_76649"},{"id":"A158","pred":"chebi_id","subj":"T158","obj":"http://purl.obolibrary.org/obo/CHEBI_16990"}],"text":" Fu, 202066Third People’s Hospital of Kunming (Kunming)YunnanDates: 1/26/2020-2/15/2020Last follow-up: NR n = 36Survival: 17% discharged, 6% ICU, 78% still hospitalized.Inclusion: Inpatients with COVID-19 based RT-PCR.Age: 45 ySex: 55.6% femalesGI/liver comorbidities: NRDisease severity: mild 11% (4), common 83% (30), severe, critical 6% (2) Diarrhea: % (3)Present on admissionVomiting, nausea, and abdominal pain: NR AST 11.1% (4)ALT 11.1% (4)Bilirubin 30.56% (11)"}

{"project":"LitCovid-PD-HP","denotations":[{"id":"T359","span":{"begin":344,"end":352},"obj":"Phenotype"},{"id":"T360","span":{"begin":389,"end":395},"obj":"Phenotype"},{"id":"T361","span":{"begin":401,"end":415},"obj":"Phenotype"}],"attributes":[{"id":"A359","pred":"hp_id","subj":"T359","obj":"http://purl.obolibrary.org/obo/HP_0002014"},{"id":"A360","pred":"hp_id","subj":"T360","obj":"http://purl.obolibrary.org/obo/HP_0002018"},{"id":"A361","pred":"hp_id","subj":"T361","obj":"http://purl.obolibrary.org/obo/HP_0002027"}],"text":" Fu, 202066Third People’s Hospital of Kunming (Kunming)YunnanDates: 1/26/2020-2/15/2020Last follow-up: NR n = 36Survival: 17% discharged, 6% ICU, 78% still hospitalized.Inclusion: Inpatients with COVID-19 based RT-PCR.Age: 45 ySex: 55.6% femalesGI/liver comorbidities: NRDisease severity: mild 11% (4), common 83% (30), severe, critical 6% (2) Diarrhea: % (3)Present on admissionVomiting, nausea, and abdominal pain: NR AST 11.1% (4)ALT 11.1% (4)Bilirubin 30.56% (11)"}

{"project":"LitCovid-sentences","denotations":[{"id":"T745","span":{"begin":0,"end":67},"obj":"Sentence"},{"id":"T746","span":{"begin":68,"end":121},"obj":"Sentence"},{"id":"T747","span":{"begin":122,"end":179},"obj":"Sentence"},{"id":"T748","span":{"begin":180,"end":222},"obj":"Sentence"},{"id":"T749","span":{"begin":223,"end":231},"obj":"Sentence"},{"id":"T750","span":{"begin":232,"end":467},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":" Fu, 202066Third People’s Hospital of Kunming (Kunming)YunnanDates: 1/26/2020-2/15/2020Last follow-up: NR n = 36Survival: 17% discharged, 6% ICU, 78% still hospitalized.Inclusion: Inpatients with COVID-19 based RT-PCR.Age: 45 ySex: 55.6% femalesGI/liver comorbidities: NRDisease severity: mild 11% (4), common 83% (30), severe, critical 6% (2) Diarrhea: % (3)Present on admissionVomiting, nausea, and abdominal pain: NR AST 11.1% (4)ALT 11.1% (4)Bilirubin 30.56% (11)"}

{"project":"LitCovid-PubTator","denotations":[{"id":"2263","span":{"begin":17,"end":23},"obj":"Species"}],"attributes":[{"id":"A2263","pred":"tao:has_database_id","subj":"2263","obj":"Tax:9606"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":" Fu, 202066Third People’s Hospital of Kunming (Kunming)YunnanDates: 1/26/2020-2/15/2020Last follow-up: NR n = 36Survival: 17% discharged, 6% ICU, 78% still hospitalized.Inclusion: Inpatients with COVID-19 based RT-PCR.Age: 45 ySex: 55.6% femalesGI/liver comorbidities: NRDisease severity: mild 11% (4), common 83% (30), severe, critical 6% (2) Diarrhea: % (3)Present on admissionVomiting, nausea, and abdominal pain: NR AST 11.1% (4)ALT 11.1% (4)Bilirubin 30.56% (11)"}